Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.73 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.73 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.73 |
| ▸ | PIM1 | P11309 | 8/20 | 0.58 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.47 |
| ▸ | CCNH | P51946 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10458766 | 0.93 | IRAK4 (0.64) | IRAK4MAPK8MAPK9PIM1IRAK1 | |
| SCHEMBL10459245 | 0.84 | PIM1 (0.59) | IRAK4MAPK8MAPK9PIM1FLT3 | |
| SCHEMBL9882108 | 0.83 | PIM1 (0.53) | IRAK4MAPK8MAPK9PIM1 | |
| SCHEMBL15745882 | 0.81 | PIM1 (0.69) | IRAK4MAPK8MAPK9PIM1FLT3 | |
| SCHEMBL10459443 | 0.80 | PIM1 (0.53) | IRAK4MAPK8MAPK9PIM1CCNT1 | |
| SCHEMBL10459312 | 0.79 | IRAK4 (0.47) | IRAK4MAPK8MAPK9PIM1HRH3 | |
| SCHEMBL10459208 | 0.78 | PIM1 (0.49) | IRAK4MAPK8MAPK9PIM1IRAK1 | |
| SCHEMBL10459431 | 0.76 | CCNT1 (0.50) | IRAK4MAPK8MAPK9PIM1CCNT1 | |
| SCHEMBL10459258 | 0.76 | IRAK4 (0.52) | IRAK4MAPK8MAPK9PIM1CCNT1 | |
| SCHEMBL10459261 | 0.75 | IRAK4 (0.49) | IRAK4MAPK8MAPK9PIM1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-9029546-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029546-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-29 | — | — | US | disclosed |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-07-19 | — | — | US | disclosed |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | IRAK4 477/4885MAPK8 242/4885MAPK9 123/4885 |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | IRAK4 477/4885MAPK8 242/4885MAPK9 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.